The Wyss Institute for Biologically Inspired Engineering at Harvard University revealed on Wednesday that it has entered into an agreement with GBS Inc to validate and de-risk its eRapid technology for SARS-CoV-2 detection.

In conjunction, Wyss would integrate its eRapid technology with GBS Inc's proprietary transistor sensor technology to enable simultaneous electrochemical sensing of multiple biomarkers related to SARS-CoV-2 infection in point-of-care COVID-19 diagnostic applications.

Additionally, eRapid was developed by the Wyss team as a low-cost, affinity-based electrochemical sensing platform that can simultaneously detect and quantify of a broad range of biomarkers for detection of comprehensive COVID-19 biomarker detection technology. The eRapid technology uses a novel, low-cost, antifouling nanocomposite coating to which SARS-CoV-2-specific ligands may be attached.

The Wyss Institute for Biologically Inspired Engineering at Harvard University uses Nature's design principles to develop bioinspired materials and devices that will transform medicine and create a more sustainable world.